Biomet reports loss on special charges

Back to TopCommentsE-mailPrintBookmark and Share

Biomet Inc. yesterday reported a $170.9 million loss in its fiscal fourth quarter as the result of more than $300 million in special charges.

For the period ended May 31, the Warsaw-based manufacturer of orthopedic products reported $103 million in charges related to its 2007 merger with LVB Acquisition LLC, a private-equity consortium partly managed by The Blackstone Group and Goldman Sachs & Co.

The company also took a $102 million charge related to its dental-reconstruction business and a $64 million charge related to legal fees.

Excluding the special charges, Biomet had profit of $66.3 million, a 72-percent increase from the same period a year ago.

Revenue in the fiscal fourth quarter increased 1 percent, to $639.3 million.
For the fiscal year, Biomet reported a loss of $749.2 million, compared with a $1 billion loss in 2008. Revenue increased 5 percent, to $2.5 billion.



Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ